Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2540)	4/22/2008 7:31:54 PM
From: Biotech Jim	Respond to of 3158

Rick- I was wondering if anyone was going to respond to my speculations... Ok, let's discuss. <The phase II trial failed, as we know. But, if a pharma (MRK or otherwise) were interested?????..... wouldn't they try to repeat (and explain) the mouse results of Golde et al.?> First off, I personally know Todd Golde (while he was at Case)and I certainly believe in his work as reproducible. Mouse results do not always translate to man, FWIW. For the various coxibs, there have been studies where CNS exposures have been adequate, whereas others do not enter the CNS well, or get pumped out by the P-glycoprotein. I understand that Searle/Monsanto (after the merger) under Needleman had an interest in examining efficacy in AD and that study with celebrex came up short, since it was not pursued further. So, if flurbie works by the coxib mechanism in AD, I would expect a failure. On the other hand, they would attempt to understand how it may have worked in mice. Not an easy task though. A while back MRK published in PNAS I believe many mouse mechanisms related to AD and is in the process of pursuing these. They are not too talkative about their approaches, but I understand there is work ongoing on MCI. BJ